The global pharmaceutical industry is at a pivotal moment. As business models evolve, regulatory scrutiny intensifies, and the pace of innovation accelerates, pharma leaders face growing pressure to transform how their organizations operate. Generative AI (GenAI) is emerging as a game-changer, redefining the way content is created, workflows are orchestrated, and decisions are made.
For many years, Global Capability Centers (GCCs) have been pegged as the north star for achieving operational efficiency and scalability. But the foundational cost advantages of GCCs—centralization, scale, labor arbitrage—are rapidly eroding. Rising attrition, stagnant innovation, and high fixed costs are exposing cracks in the GCC model.
The solution is not incremental improvement. It's a strategic rethink. Functional Capability Centers (FCCs) offer a future-ready model that is domain-specific, agile, and GenAI-enabled. FCCs bring together specialized talent, modular AI agents, and flexible partner ecosystems to deliver high-value outcomes across Commercial, Medical Affairs, Clinical, Regulatory, and Pharmacovigilance functions.
This whitepaper explores why now is the time to pivot from traditional GCCs to GenAI-powered FCCs and how forward-looking pharma organizations can lead this transformation.
GCCs are centralized, in-house hubs created by multinational enterprises to provide a broad spectrum of specialized support services. The services range from traditional enterprise functions, such as IT, finance, HR operations, and data analytics, to industry-specific capabilities like research and development (R&D), clinical operations, regulatory affairs, medical writing, pharmacovigilance, and commercial operations, that require domain knowledge and expertise.
Originally created to achieve cost efficiencies through labor arbitrage and process standardization, GCCs have evolved significantly over time. They are now seen as strategic assets playing a role at scaling global operations, influencing enterprise strategy, and enabling transformation – not just supporting it. However, as expectations evolve, cracks are beginning to surface.
Despite the initial promise, most pharma GCCs today are struggling to deliver sustained strategic value, facing critical challenges that undermine their original objectives.
The rising cost base, coupled with the ongoing issues of talent retention and innovation stagnation raises concerns that the GCC model, especially when fully internalized, may shift from being a cost arbitrage play into a potential financial and agility liability.
Considering these challenges, a more dynamic and adaptive operational model is gaining traction: the Functional Capability Center (FCC).
An FCC is a specialized, domain-centric hub that centralizes domain-specific business functions that require specialized execution. Unlike traditional GCCs that aim for broader functional coverage, FCCs focus on building deep domain capabilities in high impact and often regulated business functions such as Commercial Operations, Medical Affairs, Regulatory Submissions, and Pharmacovigilance. FCCs can either be either managed completely inhouse or in a hybrid model that combines in-house leadership with external partnerships for execution. The hybrid FCC model leverages partner ecosystems for talent, technology, and operational agility, addressing the limitations of GCCs or in-house FCCs to achieve best-in-class talent on demand, improved retention, accelerated innovation, robust compliance, while also ensuring cost efficiency.
The goal of an FCC is to deliver expertise + agility + innovation + scalability minus the overheads of traditional GCCs.
The true potential of FCCs comes to life when powered by GenAI. GenAI-enabled FCCs can fundamentally how work gets done moving from manual execution to intelligent automation.
The scope of GenAI agents is no longer limited to traditional task bots. They can handle complex tasks like scientific summarization, content generation, and workflow orchestration. They don’t just execute; they learn, adapt, and optimize over time to maximize innovation and functional value. GenAI agents shift the role of human experts to judgment and oversight, bringing scale, speed, and real-time responsiveness to life sciences operations.

Here are some of the areas where GenAI can be applied to within the core pharma functions

In GenAI-enabled FCCs, humans and agents collaborate to deliver business outcomes. FCCs evolve to include new roles like agent trainers, orchestration leads, and hybrid process designers, ensuring alignment between business goals and AI execution. Modular agent clusters further enable pharma enterprises to rapidly scale up or down in response to dynamically changing business requirements.
When powered by GenAI, FCCs evolve into adaptive intelligence hubs capable of delivering exponential value across pharma functions. With GenAI at the core of FCCs, traditional GCCs can quickly move from delivering cost efficiency to driving functional transformation, enabling pharma organizations to stay agile, innovative, and future-ready.
The GenAl-Enabled FCC Design Principles

The move to GenAI-enabled FCCs is more than just an operational adjustment; it is a strategic necessity for the future of pharma. Over the past decade, Indegene has partnered with over 30 life sciences organizations, designing and managing their Global Delivery Centers (GDCs). Across these engagements, we have observed a consistent pattern: FCCs offer greater agility, depth, strategic value, and foster continuous innovation. The integration of GenAI further amplifies this value, accelerating the transformation agenda and unlocking next-level performance.
Fundamentally, FCCs shift the focus from infrastructure to outcomes. They are more than just an alternative to GCCs; they represent an evolution in operational strategy. This hybrid model brings in strategic agility, promotes innovation, and accelerates transformation in functions that have traditionally encountered inadequate support from established operational frameworks.
The future of pharmaceutical operati ons is going to be specialized, intelligent, and driven by AI. As pharma leaders confront rising complexity, cost pressures, as well as innovation and ROI mandates, the legacy GCC model is no longer delivering the effectiveness it once promised. While GCCs remain effective for enterprise-wide support functions like IT, HR, finance, and data operations, FCCs offer a smarter, purpose-built approach for specialized functions, designed to align closely with their business needs.
The transformational impact of Generative AI makes this shift even more compelling. GenAI agents empower functional teams, by handling complex tasks and freeing up experts to focus on critical strategic thinking, innovation, and complex decision-making. It brings unmatched speed and capacity to pharma operations. Hybrid GenAI-powered FCCs take it one notch higher as they provide the flexibility to scale quickly, access cutting-edge technology, and integrate innovation without heavy internal investments.
Pharma leaders who embrace purpose-built hybrid FCCs powered by Generative AI can shift from infrastructure-heavy support to a nimble, innovation-driven model that accelerates breakthroughs, improves patient outcomes, and positions their organizations to thrive in the next era of healthcare.
1. CIEL HR Study (2025). India’s GCCs Face Talent Retention Crisis Amid Shifting Workforce Dynamics. https://cielhr.com/wp-content/uploads/2025/07/51-of-GCCs-in-India-Cite-Talent-Retention-as-Top-Concern-Reveals-Latest-Study-by-CIEL-HR.pdf
2. The New Indian Express (2025). GCCs to see average salary hike of 9.9% in 2025. https://www.newindianexpress.com/business/2025/May/06/gccs-to-see-average-salary-hike-of-99-in-2025
3. Business Standard (2025). Staff costs hurt India’s global capability centres as maturity curve lags. https://www.business-standard.com/industry/news/indian-gcc-struggle-with-higher-salary-costs-even-as-maturity-eludes-125061500460_1.html
4. BCG (2025). Rewriting the Global Capability Center playbook. Scaling Maturity with AI. https://web-assets.bcg.com/66/c2/16f4539648f0a6a455ce5058f7f2/rewriting-the-global-capability-center-playbook.pdf
5. SSON Research & Analytics (2024). Six Reasons Why New Global Capability Centers Struggle to Establish Themselves. https://www.sson-analytics.com/shared-services-gbs-best-practices/blog-entries/six-reasons-why-new-globalcapability-centers-struggle-to-establish-themselves